Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.93

€1.93

4.090%
0.076
4.090%
-
 
09:07 / Tradegate WKN: A14158 / Name: CytomX / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Cytomx Therapeutics Inc Stock

A very strong showing by Cytomx Therapeutics Inc today, with an increase of €0.076 (4.090%) compared to yesterday's price.
Our community identified positive and negative aspects for Cytomx Therapeutics Inc stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Cytomx Therapeutics Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.

Pros and Cons of Cytomx Therapeutics Inc in the next few years

Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Cytomx Therapeutics Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Cytomx Therapeutics Inc 4.090% -8.743% -11.524% 60.449% 79.691% 13.570% -70.722%
Krystal Biotech 0.770% -12.948% -3.635% -29.196% -23.357% 44.907% -
Ardelyx Inc. -1.210% 17.403% 23.030% -19.676% -10.050% 436.908% -7.287%
Evolus Inc 0.000% -32.692% -30.464% -56.250% -50.000% -41.341% 89.326%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

CytomX Therapeutics, a player in the biotechnology and medical research sector, presents a mixed bag of financial indicators. On one hand, the market capitalization suggests a relatively modest valuation for its potential; however, the financial statements reveal significant liabilities, negative equity, and consecutive years of net losses, raising some eyebrows about the overall financial health of the company. Diving deeper into the financials showcases the complexities and challenges CytomX faces in navigating the robust landscape of biotechnology.

Research and Development Investment: In the 2023 fiscal year, CytomX allocated $77.68 million toward research and development (R&D). This commitment signals a strong dedication to innovation, crucial for biotech companies that rely on the successful development of new therapies and drugs.

Market Capitalization: With a market capitalization of approximately $98.88 million, CytomX is positioned within a valuation range that reflects cautious optimism from investors. While market size alone doesn’t ensure sustainable growth, it reflects potential that could be unlocked with successful product launches or partnerships.